Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
US |
|
A
|
Advantest Corp
XMUN:VAN
|
JP |
|
F
|
Fanuc Corp
XMUN:FUC
|
JP |
Intrinsic Value
The intrinsic value of Regeneron Pharmaceuticals Inc (REGN) under the Base Case is 604.62 USD per share.
Compared with the current market price of 924.6 USD, the stock appears
Overvalued by 35% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Regeneron Pharmaceuticals Does
Regeneron Pharmaceuticals makes prescription medicines, mostly biologic drugs that are built from antibodies and other protein-based therapies. It develops treatments for eye diseases, allergies, inflammation, cancer, and rare genetic disorders, then sells them through hospitals, clinics, pharmacies, and specialty distributors. Its main customers are patients and the doctors and health systems that treat them, along with insurers and government health programs that pay for the drugs.
- Headquarters
- United States of America US
- Employees
- 15 410
- IPO date
- Apr 2, 1991
Regeneron Pharmaceuticals has a narrow economic moat
Legal protection for medicines such as Dupixent and EYLEA HD prevents rivals from freely copying them, helping Regeneron preserve sales and profits. This protection covers specific medicines rather than whole treatment markets, where competing drugs remain available.
Read the full moat analysis
Revenue & Expenses Breakdown
Regeneron Pharmaceuticals Inc
Earnings Waterfall
Regeneron Pharmaceuticals Inc
The intrinsic value for Regeneron Pharmaceuticals Inc (REGN) under the Base Case is 604.62 USD.
Compared with the current market price of 924.6 USD, the stock appears Overvalued by 35% .